Cerexa

Cerexa was a privately held biopharmaceutical company founded in the mid-2000s (its cerexa.com domain was registered in March 2005) to develop anti-infective therapies for serious, drug-resistant bacterial infections in the hospital setting. Its lead program was ceftaroline fosamil, a fifth-generation cephalosporin antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA), in-licensed from Takeda Pharmaceutical Company and carried forward by Forest Laboratories; the compound was approved by the FDA on October 29, 2010 and marketed as Teflaro in the United States and Zinforo in Europe. Cerexa was backed by venture investors including Canaan Partners, and its programs ultimately passed through Forest Laboratories into the Actavis/Allergan combination (Forest Laboratories was acquired by Actavis on July 1, 2014) and on to AbbVie. Cerexa no longer operates as an independent company and has no developer surface: it publishes no API, no SDKs, no GitHub organization and no documentation, and its historical cerexa.com domain is now registered and operated by AbbVie, 301-redirecting to AbbVie's Allergan page. This profile is retained as a historical company record in the API Evangelist network.

Cerexa is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Anti-Infectives, and Antibiotics.

🌐 Visit website 📡 Source on GitHub

3.3/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-21 · rubric v0.12.0

0 APIs

Company Biotechnology Pharmaceuticals Anti-Infectives Antibiotics Life Sciences Healthcare Acquired

Kin Score

Kin Score How this is scored →
scored 2026-08-21 · rubric v0.12.0

Composite quality — 3.3/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cerexa: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Source (apis.yml)

aid: cerexa
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/cerexa.png
name: Cerexa
description: 'Cerexa was a privately held biopharmaceutical company founded in the mid-2000s (its cerexa.com domain was registered
  in March 2005) to develop anti-infective therapies for serious, drug-resistant bacterial infections in the hospital setting.
  Its lead program was ceftaroline fosamil, a fifth-generation cephalosporin antibiotic active against methicillin-resistant
  Staphylococcus aureus (MRSA), in-licensed from Takeda Pharmaceutical Company and carried forward by Forest Laboratories;
  the compound was approved by the FDA on October 29, 2010 and marketed as Teflaro in the United States and Zinforo in Europe.
  Cerexa was backed by venture investors including Canaan Partners, and its programs ultimately passed through Forest Laboratories
  into the Actavis/Allergan combination (Forest Laboratories was acquired by Actavis on July 1, 2014) and on to AbbVie. Cerexa
  no longer operates as an independent company and has no developer surface: it publishes no API, no SDKs, no GitHub organization
  and no documentation, and its historical cerexa.com domain is now registered and operated by AbbVie, 301-redirecting to
  AbbVie''s Allergan page. This profile is retained as a historical company record in the API Evangelist network.'
url: https://raw.githubusercontent.com/api-evangelist/cerexa/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-status-detail: No independent operations and no API surface. Programs passed through Forest Laboratories into Actavis/Allergan
  and are now held by AbbVie, which also controls the legacy cerexa.com domain.
x-successor: abbvie
x-legacy-domain: cerexa.com
x-legacy-domain-redirects-to: https://www.abbvie.com/allergan.html
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Anti-Infectives
- Antibiotics
- Life Sciences
- Healthcare
- Acquired
apis: []
common:
- type: DomainSecurity
  url: security/cerexa-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 2
  pass: local-v1

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/cerexa"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/cerexa/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/cerexa/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.